Details for Patent: 8,937,057

Title:	Combination of azelastine and mometasone for nasal administration
Abstract:	A pharmaceutical product or formulation, which comprises azelastine or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, and a steroid, or a pharmaceutical acceptable salt, solvate or physiologically functional derivative thereof, preferably the product or formulation being in a form suitable for nasal or ocular administration.
Inventor(s):	Lulla; Amar (Mumbai, IN), Malhotra; Geena (Mumbai, IN)
Assignee:	Cipla Limited (Mumbai, IN)
Filing Date:	Oct 03, 2012
Application Number:	13/644,127
Claims:	1. A method for the prophylaxis or treatment in a mammal of a condition for which administration of one or more anti-histamines and/or one or more steroids is indicated, comprising intranasal administration to said mammal of a therapeutically effective amount of a pharmaceutical composition comprising (a) azelastine, or a pharmaceutically acceptable salt thereof; and (b) a pharmaceutically acceptable ester of mometasone, wherein the pharmaceutical composition is in a dosage form suitable for nasal administration. 2. The method of claim 1, wherein the dosage form suitable for nasal administration is in the form of an aerosol, an ointment, nasal drops, or a nasal spray or an inhalation solution. 3. The method of claim 1, wherein the dosage form suitable for nasal administration comprises nasal spray. 4. The method of claim 1, wherein the dosage form suitable for nasal administration comprises nasal drops. 5. The method of claim 1, wherein the pharmaceutical composition is the form of an aqueous suspension or solution. 6. The method of claim 1, wherein the pharmaceutical composition has a particle size of less than 10 .mu.m. 7. The method of claim 1, wherein the pharmaceutically acceptable salt of azelastine is azelastine hydrochloride. 8. The method of claim 1, wherein the pharmaceutically acceptable ester of mometasone is mometasone furoate or mometasone furoate monohydrate. 9. The method of claim 1, wherein the pharmaceutically acceptable salt of azelastine is azelastine hydrochloride and the pharmaceutically acceptable ester of mometasone is mometasone furoate. 10. The method of claim 1, wherein the pharmaceutically acceptable salt of azelastine is azelastine hydrochloride and the pharmaceutically acceptable ester of mometasone is mometasone furoate monohydrate. 11. The method of claim 1, wherein the pharmaceutical composition further comprises at least one additive selected from the group consisting of a surfactant, an isotonic agent, a buffer, a preservative, and a suspending agent or a thickening agent, and combinations thereof. 12. The method of claim 11, wherein the surfactant is selected from the group consisting of a polysorbate surfactant, poloxamer surfactant, and combinations thereof. 13. The method of claim 11, wherein the isotonic agent is selected from the group consisting of sodium chloride, saccharose, glucose, glycerine, sorbitol, 1,2-propylene glycol, and combinations thereof. 14. The method of claim 11, wherein the buffer comprises a citric acid-citrate buffer. 15. The method of claim 11, wherein the preservative is selected from the group consisting of edetic acid and its alkali salts, lower alkyl p-hydroxybenzoates, chlorhexidine, phenyl mercury borate, or benzoic acid or a salt thereof, a quaternary ammonium compound, sorbic acid or a salt thereof, and combinations thereof. 16. The method of claim 11, wherein the suspending agent or thickening agent is selected from the group consisting of cellulose derivatives, gelatin, polyvinylpyrrolidone, tragacanth, ethoxose, alginic acid, polyvinyl alcohol, polyacrylic acid, pectin, and combinations thereof. 17. The method of claim 11, wherein the buffer, when present, maintains the pH of the aqueous phase at from 3 to 7. 18. The method of claim 1, wherein the mammal is a human. 19. The method of claim 1, wherein the condition is allergic rhinitis. 20. The method of claim 1, wherein the condition is allergic conjunctivitis. 21. The method of claim 1, wherein the pharmaceutical composition is formulated for use as a nasal spray or nasal drops in the treatment of seasonal allergic rhinitis or perennial allergic rhinitis. 22. The method of claim 1, wherein the pharmaceutical composition is formulated for use as a nasal spray or nasal drops in the treatment of seasonal allergic conjunctivitis or perennial allergic conjunctivitis. 23. The method of claim 9, wherein the pharmaceutical composition is formulated for use as a nasal spray or nasal drops in the treatment of seasonal allergic rhinitis or perennial allergic rhinitis. 24. The method of claim 10, wherein the pharmaceutical composition is formulated for use as a nasal spray or nasal drops in the treatment of seasonal allergic rhinitis or perennial allergic rhinitis. 25. The method of claim 9, wherein the pharmaceutical composition is formulated for use as a nasal spray or nasal drops in the treatment of seasonal allergic conjunctivitis or perennial allergic conjunctivitis. 26. The method of claim 10, wherein the pharmaceutical composition is formulated for use as a nasal spray or nasal drops in the treatment of seasonal allergic conjunctivitis or perennial allergic conjunctivitis. 27. The method of claim 1, wherein the condition is seasonal allergic rhinitis. 28. The method of claim 1, wherein the condition is perennial allergic rhinitis. 29. The method of claim 1, wherein the condition is seasonal allergic conjunctivitis. 30. The method of claim 1, wherein the condition is perennial allergic conjunctivitis.